Published in J Clin Oncol on April 01, 2006
Guidelines for the diagnosis and treatment of malignant pleural mesothelioma. J Thorac Dis (2013) 1.27
New and emerging therapeutic options for malignant pleural mesothelioma: review of early clinical trials. Cancer Manag Res (2015) 1.19
Management of malignant pleural mesothelioma-The European experience. J Thorac Dis (2014) 1.14
Four-gene expression ratio test for survival in patients undergoing surgery for mesothelioma. J Natl Cancer Inst (2009) 1.06
Increased efficacy of doxorubicin delivered in multifunctional microparticles for mesothelioma therapy. Int J Cancer (2010) 1.02
FDG PET/CT patterns of treatment failure of malignant pleural mesothelioma: relationship to histologic type, treatment algorithm, and survival. Eur J Nucl Med Mol Imaging (2011) 0.99
The evolution of multimodality therapy for malignant pleural mesothelioma. Curr Treat Options Oncol (2011) 0.88
Mesothelioma cells escape heat stress by upregulating Hsp40/Hsp70 expression via mitogen-activated protein kinases. J Biomed Biotechnol (2009) 0.85
Genes associated with prognosis after surgery for malignant pleural mesothelioma promote tumor cell survival in vitro. BMC Cancer (2011) 0.85
Anaesthetic management of cytoreductive surgery followed by hyperthermic intrathoracic chemotherapy perfusion. J Cardiothorac Surg (2014) 0.84
Current surgical strategies for malignant pleural mesothelioma. Surg Today (2015) 0.84
Reactive oxygen species a double-edged sword for mesothelioma. Oncotarget (2015) 0.82
Extrapleural pneumonectomy or pleurectomy/decortication for malignant pleural mesothelioma. Gen Thorac Cardiovasc Surg (2014) 0.81
A multifunctional mesothelin antibody-tagged microparticle targets human mesotheliomas. J Histochem Cytochem (2012) 0.79
Standardizing surgical treatment in malignant pleural mesothelioma. Ann Cardiothorac Surg (2012) 0.79
Simple intrapleural hyperthermia at thoracoscopic exploration to treat malignant pleural effusion. J Cardiothorac Surg (2015) 0.77
Making the case for molecular staging of malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg (2009) 0.75
Management of malignant pleural mesothelioma-part 2: therapeutic approaches : Consensus of the Austrian Mesothelioma Interest Group (AMIG). Wien Klin Wochenschr (2016) 0.75
Multimodality therapy for malignant pleural mesothelioma. Ann Cardiothorac Surg (2012) 0.75
Clinical outcomes of cytoreductive surgery combined with intrapleural perfusion of hyperthermic chemotherapy in advanced lung adenocarcinoma with pleural dissemination. J Thorac Dis (2016) 0.75
Intraoperative adjuncts for malignant pleural mesothelioma. Transl Lung Cancer Res (2017) 0.75
Extrapleural pneumonectomy (EPP) vs. pleurectomy decortication (P/D). Ann Transl Med (2017) 0.75
Pleurectomy and decortication. Ann Transl Med (2017) 0.75
Intraoperative intracavitary hyperthermic chemotherapy for malignant pleural mesothelioma. Ann Transl Med (2017) 0.75
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 61.56
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med (2010) 36.78
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science (2007) 32.68
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med (2005) 26.35
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol (2009) 15.23
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med (2013) 14.78
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med (2008) 14.47
Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell (2012) 11.69
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol (2005) 9.95
First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol (2008) 9.43
EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res (2008) 9.29
An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays. Cancer Res (2004) 8.86
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol (2012) 8.64
LKB1 modulates lung cancer differentiation and metastasis. Nature (2007) 7.80
Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell (2010) 7.78
SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet (2009) 7.48
Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res (2009) 7.35
Aging and environmental exposures alter tissue-specific DNA methylation dependent upon CpG island context. PLoS Genet (2009) 7.07
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature (2009) 7.05
Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. Nat Med (2006) 6.96
Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res (2005) 6.93
Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res (2008) 6.91
Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med (2012) 6.77
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol (2011) 6.69
ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci U S A (2005) 6.35
Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med (2010) 6.28
Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med (2005) 6.04
Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J Clin Invest (2006) 5.73
Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol (2009) 5.70
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A (2003) 5.49
PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res (2007) 5.45
The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell (2006) 5.34
Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255. Cancer Res (2004) 5.23
Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. Cancer Cell (2007) 4.85
Transcriptome sequencing of malignant pleural mesothelioma tumors. Proc Natl Acad Sci U S A (2008) 4.75
The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups. J Thorac Cardiovasc Surg (2012) 4.68
A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res (2010) 4.51
Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med (2011) 4.51
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A (2008) 4.43
Video-assisted thoracic surgery lobectomy: report of CALGB 39802--a prospective, multi-institution feasibility study. J Clin Oncol (2007) 4.42
A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res (2011) 4.22
Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma. Int J Radiat Oncol Biol Phys (2006) 4.22
Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. J Natl Cancer Inst (2005) 4.19
Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res (2006) 4.11
Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Proc Natl Acad Sci U S A (2009) 4.02
Non-small cell lung cancer. J Natl Compr Canc Netw (2010) 3.93
Translation of microarray data into clinically relevant cancer diagnostic tests using gene expression ratios in lung cancer and mesothelioma. Cancer Res (2002) 3.90
Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res (2009) 3.65
Double unrelated reduced-intensity umbilical cord blood transplantation in adults. Biol Blood Marrow Transplant (2007) 3.58
Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol (2007) 3.50
Circumventing cancer drug resistance in the era of personalized medicine. Cancer Discov (2012) 3.25
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature (2012) 3.24
The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat Med (2013) 3.20
Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res (2004) 3.20
The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. Cancer Res (2010) 3.16
Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J Clin Oncol (2010) 3.15
The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer (2010) 3.03
Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol (2006) 2.82
Combined use of ALK immunohistochemistry and FISH for optimal detection of ALK-rearranged lung adenocarcinomas. J Thorac Oncol (2013) 2.68
ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. Clin Cancer Res (2013) 2.65
Non-small cell lung cancer, version 2.2013. J Natl Compr Canc Netw (2013) 2.56
Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies. J Thorac Cardiovasc Surg (2004) 2.53
Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression. Cancer Res (2005) 2.49
Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial. J Clin Oncol (2007) 2.48
Missense mutations of the BRAF gene in human lung adenocarcinoma. Cancer Res (2002) 2.48
Amplification of chromosomal segment 4q12 in non-small cell lung cancer. Cancer Biol Ther (2009) 2.47
Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors. Cancer Discov (2012) 2.47
Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med (2012) 2.46
Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models. Cancer Res (2007) 2.45
Gene expression in lung adenocarcinomas of smokers and nonsmokers. Am J Respir Cell Mol Biol (2003) 2.45
Non-small cell lung cancer. J Natl Compr Canc Netw (2012) 2.40